Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth [ATAC-seq]

ABSTRACT: SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth [ATAC-seq]

PROVIDER: PRJNA902504 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth

Project description:SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth

| PRJNA903471 | ENA

SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth

Project description:SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth

| PRJNA902395 | ENA

SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth

Project description:Malignant rhabdoid tumor (MRT) is a highly malignant and often lethal childhood cancer. MRTs are genetically defined by bi-allelic inactivating mutations in SMARCB1, a member of the BRG1/BRM-associated factors (BAF) chromatin remodeling complex. Here, we studied derailed regulatory landscapes as a consequence of SMARCB1 loss in the context of MRT. Our multi-omics approach on patient-derived MRT organoids revealed a dramatic reshaping of the regulatory landscape upon SMARCB1 reconstitution. Chromosome conformation capture experiments subsequently revealed patient-specific looping of distal enhancer regions with the promoter of the MYC oncogene and validation of this data in patients with combined single-cell RNA-seq and ATAC-seq.

2023-10-19 | GSE218385 | GEO

SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth [RNA-seq]

Project description:SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth [RNA-seq]

| PRJNA902506 | ENA

SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth [Hi-C]

Project description:SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth [Hi-C]

| PRJNA902502 | ENA

SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth [4C-seq]

Project description:SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth [4C-seq]

| PRJNA902505 | ENA

SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth [ChIP-seq]

Project description:SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth [ChIP-seq]

| PRJNA902503 | ENA

SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth [4C-seq]

Project description:Malignant rhabdoid tumor (MRT) is a highly malignant and often lethal childhood cancer. MRTs are genetically defined by bi-allelic inactivating mutations in SMARCB1, a member of the BRG1/BRM-associated factors (BAF) chromatin remodeling complex. Mutations in BAF complex members are common in human cancer. Yet, their contribution to tumorigenesis remains in many cases poorly understood. Here, we studied derailed regulatory landscapes as a consequence of SMARCB1 loss in the context of MRT. Our multi-omics approach on patient-derived MRT organoids revealed a dramatic reshaping of the regulatory landscape upon SMARCB1 reconstitution. Chromosome conformation capture experiments subsequently revealed patient-specific looping of distal enhancer regions with the promoter of the MYC oncogene. This intertumoral heterogeneity in MYC enhancer utilization is also present in patient MRT tissues as shown by combined single-cell RNA-seq and ATAC-seq. We show that loss of SMARCB1 drives patient-specific epigenetic reprogramming underlying MRT tumorigenesis.

2023-10-20 | GSE218110 | GEO

SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth [RNA-seq]

Project description:Malignant rhabdoid tumor (MRT) is a highly malignant and often lethal childhood cancer. MRTs are genetically defined by bi-allelic inactivating mutations in SMARCB1, a member of the BRG1/BRM-associated factors (BAF) chromatin remodeling complex. Mutations in BAF complex members are common in human cancer. Yet, their contribution to tumorigenesis remains in many cases poorly understood. Here, we studied derailed regulatory landscapes as a consequence of SMARCB1 loss in the context of MRT. Our multi-omics approach on patient-derived MRT organoids revealed a dramatic reshaping of the regulatory landscape upon SMARCB1 reconstitution. Chromosome conformation capture experiments subsequently revealed patient-specific looping of distal enhancer regions with the promoter of the MYC oncogene. This intertumoral heterogeneity in MYC enhancer utilization is also present in patient MRT tissues as shown by combined single-cell RNA-seq and ATAC-seq. We show that loss of SMARCB1 drives patient-specific epigenetic reprogramming underlying MRT tumorigenesis.

2023-10-20 | GSE218114 | GEO

SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth [Hi-C]

Project description:Malignant rhabdoid tumor (MRT) is a highly malignant and often lethal childhood cancer. MRTs are genetically defined by bi-allelic inactivating mutations in SMARCB1, a member of the BRG1/BRM-associated factors (BAF) chromatin remodeling complex. Mutations in BAF complex members are common in human cancer. Yet, their contribution to tumorigenesis remains in many cases poorly understood. Here, we studied derailed regulatory landscapes as a consequence of SMARCB1 loss in the context of MRT. Our multi-omics approach on patient-derived MRT organoids revealed a dramatic reshaping of the regulatory landscape upon SMARCB1 reconstitution. Chromosome conformation capture experiments subsequently revealed patient-specific looping of distal enhancer regions with the promoter of the MYC oncogene. This intertumoral heterogeneity in MYC enhancer utilization is also present in patient MRT tissues as shown by combined single-cell RNA-seq and ATAC-seq. We show that loss of SMARCB1 drives patient-specific epigenetic reprogramming underlying MRT tumorigenesis.

2023-10-20 | GSE218113 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data